Suggested remit: To appraise the clinical and cost effectiveness of capmatinib within its marketing authorisation for treating locally advanced or metastatic non-small-cell lung cancer (NSCLC) with mesenchymal–epithelial transition (MET) exon 14 (METex14) skipping mutations.
Status In progress
Process STA 2018
ID number 1387

Provisional Schedule

Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators 09 July 2021 - 06 August 2021

Project Team

Project lead Emily Richards

Email enquiries


Key events during the development of the guidance:

Date Update
15 December 2017 In progress. DHSC referral received

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance